Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS: Ponatinib in Imatinib-Resistant CML
NCT02398825Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Jun 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myeloid leukemia (CML), sponsored by GIMEMA. Started Jun 2016; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02398825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398825.